This Randomized trial assessing the Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER) therefore seeks to evaluate the efficacy and safety of MRA therapy in participants with low-renin hypertension and to evaluate the clinical, biochemical, and molecular markers that determine MRA responsiveness in people with low-renin hypertension. The gene discussed is NR3C2; the disease is Hypertension.